Calgary, AB – December 2, 2025 – TheNewswire – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises of the following additional points related to its prior News Release of November 25, 2025 regarding its application to the Alberta Securities Commission (the “ASC”, the Company’s Principal Regulator) for a Management Cease Trade Order (“MCTO”): The Company is not currently subject to a ...

Core Insights - Universal Ibogaine Inc. has temporarily closed its Kelburn Recovery Centre as part of a restructuring process aimed at exploring financing options, including potential sale or leasing of the property [1][2] - The company remains focused on its primary mission to obtain approval for ibogaine use through a planned clinical trial targeting opioid use disorder, with intentions to expand treatment protocols globally [2][3] Company Overview - Universal Ibogaine Inc. is a life sciences company dedicated to transforming addiction treatment using medicalized ibogaine, with a focus on opioid use disorder [3] - The company aims to revolutionize addiction treatment and improve the lives of individuals and families affected by addiction through planned clinical trials and future licensing agreements [3]

Group 1 - Universal Ibogaine Inc. has undergone a transition in its Board of Directors, with several members resigning to strengthen the company's foundation for future growth [1][2] - The current Board members include Eric Hrimech, Nia Killebrew, Tony Wagner, James Duncan, and Nick Karos, as the company prepares to submit its clinical trial application to Health Canada by the end of November 2025 [2] - The company aims to transform addiction treatment through medicalized ibogaine, focusing on opioid use disorder, and plans to develop a holistic addiction treatment protocol at its Kelburn Recovery Centre [4] Group 2 - Universal Ibogaine Inc. is positioned as a life sciences company with a mission to revolutionize addiction treatment and improve the lives of individuals and families affected by addiction [4] - The company is planning future licensing agreements to utilize its treatment protocol globally, indicating a strategic approach to expand its market reach [4]

Core Insights - Universal Ibogaine Inc. has appointed two new Directors, Nia Killebrew and Tony Wagner, to its Board effective August 28, 2025, filling a previously vacant position [1][2] - The Annual Meeting of Shareholders (AGM) is scheduled for September 4, 2025, where current Board member Dean Koumontzis will not stand for re-election [2] Company Overview - Universal Ibogaine Inc. is focused on transforming addiction treatment through medicalized ibogaine, with plans for a Canadian clinical trial targeting opioid use disorder [4] - The company is developing a holistic addiction treatment protocol at its Kelburn Recovery Centre, which aims to enhance the effectiveness of the ibogaine detox protocol [4]

Company Overview - Universal Ibogaine Inc. is a life sciences company focused on researching and delivering medicalized ibogaine-centered addiction care [4] - The company aims to transform addiction treatment through a planned Canadian clinical trial targeting opioid use disorder and intends to utilize this treatment protocol globally via future licensing agreements [4] Recent Developments - Ken Cranwill has resigned from the Board of Directors to focus on other business ventures, with the company expressing gratitude for his service over the past year [1] - The company has received approval from the TSX Venture Exchange to settle $106,200 in consulting fees owed to CEO Nick Karos by issuing 4,248,000 common shares at a price of $0.025 per share [2] - Following the share issuance, Universal Ibogaine will have a total of 312,858,516 common shares outstanding [2] Future Plans - The company is concurrently developing a holistic addiction treatment protocol at its Kelburn Recovery Centre, which, when combined with the ibogaine detox protocol, aims to revolutionize addiction treatment and improve the lives of affected individuals and families [4]